Categories
Connect with us on LinkedIn
PMCF requirements are raising hard questions about cost, device viability, and where AI fits in
Most PMCF programs weren't designed for EU MDR. They were built before Article 61(11) made ongoing clinical data...
Trust LLMs with Chart Review: Validation Framework
Most AI chart review vendors oversell accuracy and ignore the pipeline problem entirely. This brief shows what peer-reviewed...
Where PRO strategy goes wrong: therapeutic area fit, capture frequency, and the implementation gap that takes years to surface
Expert insights on PRO data, regulatory uncertainty, and the implementation gap that kills most ePRO strategies. Watch the...
The eCOA Iceberg: uncovering the hidden costs of software-only models
SaaS eCOA looks cheaper on paper. This guide exposes five hidden costs that change the full-service vs. software-only...
The Temporal Conundrum: Bridging the Gap Between Manual UAT and AI Automation in eCOA
Manual eCOA UAT runs 12-16 weeks because time-dependent protocol logic has to be tested across the full span...
End the surgical data entry burden: AI-assisted, human-supervised, 80% faster
On May 6, 2026, Castor and SAGES are hosting a 30-minute session on ending the surgical data entry...
Leveraging the patient voice to reduce regulatory uncertainty during submission
Learn how PRO data closes evidence gaps in FDA and EMA submissions. Join outcomes expert Ari Gnanasakthy and...
Beyond the EHR: meeting the FDA’s new real-world evidence standards
The FDA’s December 2025 device guidance and March 2026 ICH M14 adoption raise the bar for RWE programs....
Biotech AI strategy for clinical teams | LinkedIn Live
LinkedIn Live event tile featuring Derk Arts, CEO of Castor, and Solomon Babani, Founder and CEO of Symbiosis...
The ePRO blueprint for pain trials: Optimizing data capture from protocol design to efficacy endpoints
The 11-point electronic Numeric Rating Scale (eNRS) is now the preferred digital standard for BYOD pain trials, recommended...
Early-stage biotech’s AI advantage is a window that closes. Sol Babani and Derk Arts on how to use it.
Sol Babani and Derk Arts on why early-stage biotech must build AI-native operations, not retrofit old ones. Decision...
Better Evidence Starts with Better Infrastructure
Meet Castor at ISPOR US 2026 | May 17-20 | Philadelphia, PA
Schedule a meeting with the Castor team at ISPOR US 2026. See Castor Catalyst AI for real-world evidence...
Joel White’s Q4 CRO breakdown: strong bookings, a sell-off that didn’t match, and the disruption gap nobody is talking about
Q4 CRO revenues grew. Bookings accelerated. So why the AI panic? Joel White breaks down what the numbers...
What AI replaces in Phase 2/3 data management, and the edit check question your team hasn’t asked yet
Alison Bishop and Derk Arts on what AI actually replaces in Phase 2/3 data management, with a deep...
Castor adds nearly 10 commercial Phase II/III eCOA studies in H2 2025
Nearly 10 Phase II/III eCOA studies and 12 validated instruments across four therapeutic areas. Castor’s H2 2025 platform...
Data management without the coordination friction
Castor replaces disconnected DM tools and CRO handoffs with one platform and one expert team. Fixed-fee, submission-ready.
Biotech clinical trial data management
Castor delivers expert data management for biotech trials. Submission-ready from day one. No intermediary layers.
ICH E6(R3) compliance for biotech studies
See how Castor's unified platform helps biotech sponsors meet ICH E6(R3) oversight, data integrity, and site burden requirements.